Seems as though something is wrong internally with (NASDAQ:ACAD) Acadia and no one knows if the stock will recover? The stock is selling at a discount now? We now know the value of the stock is perceived to be 20+% higher by investors if a takeover is to ensue. However, the new CEO did not take this into account, NDA submission, drug approval, or demand come commercialization. ACAD could be $80 in 8-12 months from now. But they need a partner with deep pockets. Dendreon also tried to do it alone. If the science is there , ACAD should be getting knocks on the door about now. Sonal Signal: Be wary